Astera Labs (NASDAQ:ALAB) Price Target Raised to $260.00

Astera Labs (NASDAQ:ALAB) had its target price increased by Needham & Company LLC from $220.00 to $260.00 in a research report sent to investors on Wednesday, MarketBeat Ratings reports. They currently have a buy rating on the stock.

Other research analysts have also issued reports about the company. Citigroup raised their price target on Astera Labs from $200.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday. Rothschild & Co Redburn initiated coverage on Astera Labs in a research report on Friday, May 1st. They set a “neutral” rating and a $153.00 price target for the company. Weiss Ratings lowered Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 23rd. UBS Group assumed coverage on Astera Labs in a report on Tuesday, April 21st. They issued a “neutral” rating and a $180.00 target price for the company. Finally, Stifel Nicolaus lifted their target price on Astera Labs from $236.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday. Fifteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Astera Labs presently has a consensus rating of “Moderate Buy” and a consensus target price of $229.65.

Astera Labs Stock Up 2.1%

Shares of ALAB opened at $199.79 on Wednesday. The company has a market capitalization of $34.25 billion, a price-to-earnings ratio of 134.99, a PEG ratio of 3.23 and a beta of 3.35. The stock’s 50-day moving average price is $143.77 and its 200-day moving average price is $153.99. Astera Labs has a 52 week low of $69.26 and a 52 week high of $262.90.

Astera Labs (NASDAQ:ALAB) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.07. Astera Labs had a return on equity of 18.49% and a net margin of 26.72%.The business had revenue of $308.36 million during the quarter, compared to analysts’ expectations of $292.19 million. During the same quarter in the prior year, the firm earned $0.33 earnings per share. The business’s revenue was up 93.5% compared to the same quarter last year. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. As a group, equities analysts anticipate that Astera Labs will post 1.48 EPS for the current fiscal year.

Insider Transactions at Astera Labs

In related news, Director Manuel Alba sold 183,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $107.61, for a total transaction of $19,692,630.00. Following the transaction, the director owned 319,863 shares of the company’s stock, valued at $34,420,457.43. This trade represents a 36.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Philip Mazzara sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $107.77, for a total value of $1,077,700.00. Following the transaction, the general counsel directly owned 118,084 shares in the company, valued at approximately $12,725,912.68. This represents a 7.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,064,888 shares of company stock worth $150,764,723 over the last three months. 12.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Astera Labs

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its stake in shares of Astera Labs by 167.3% during the 1st quarter. Royal Bank of Canada now owns 152,453 shares of the company’s stock worth $9,097,000 after acquiring an additional 95,409 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Astera Labs by 213.4% during the 1st quarter. AQR Capital Management LLC now owns 11,391 shares of the company’s stock worth $680,000 after purchasing an additional 7,756 shares during the last quarter. Empowered Funds LLC raised its position in shares of Astera Labs by 917.3% during the 1st quarter. Empowered Funds LLC now owns 4,639 shares of the company’s stock worth $277,000 after purchasing an additional 4,183 shares during the last quarter. First Trust Advisors LP raised its position in shares of Astera Labs by 102.0% during the 2nd quarter. First Trust Advisors LP now owns 112,766 shares of the company’s stock worth $10,196,000 after purchasing an additional 56,952 shares during the last quarter. Finally, Brown Advisory Inc. raised its position in shares of Astera Labs by 54.9% during the 2nd quarter. Brown Advisory Inc. now owns 5,581 shares of the company’s stock worth $505,000 after purchasing an additional 1,977 shares during the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Key Astera Labs News

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Astera Labs to $280 from $205 and kept an overweight rating, signaling strong confidence in further upside after the company’s latest results. Benzinga
• Positive Sentiment: Needham lifted its price target to $260, while other reports cited positive forecasts from JPMorgan and Stifel, adding to the bullish analyst momentum around ALAB. Astera Labs (NASDAQ:ALAB) Price Target Raised to $260.00 at Needham & Company LLC
• Positive Sentiment: Commentary around the stock highlighted Astera Labs as a long-term momentum name and a beneficiary of AI connectivity demand, suggesting investors see durable growth tied to datacenter buildouts and server interconnect products. Why Astera Labs, Inc. (ALAB) is a Top Momentum Stock for the Long-Term
• Positive Sentiment: Several pieces emphasized strong AI connectivity demand and Scorpio expansion, with upbeat takes on the company’s positioning in the datacenter market helping support the stock. Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised
• Neutral Sentiment: Post-earnings analysis was mixed: bulls pointed to strong growth, but critics noted rising costs, competition, and a premium valuation, which could cap near-term upside. Should Investors Buy, Hold, or Sell ALAB Stock Post Q1 Earnings?
• Neutral Sentiment: Astera Labs’ Q1 2026 earnings transcript kept attention on the company’s strong revenue growth and guidance, but the transcript itself does not add a new catalyst beyond the already reported results. Astera Labs (ALAB) Q1 2026 Earnings Transcript
• Negative Sentiment: The main downside risk is valuation: after a strong run and multiple target hikes, some investors may worry the stock already prices in a lot of future growth.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.